Pancreatic ductal adenocarcinoma (PDA) is an aggressive form of pancreatic cancer with limited treatment options, largely due to a mutation in the KRAS gene found in about 95% of cases. This mutation shifts the metabolic pathways of cancer cells, producing waste products such as Reactive Oxygen Species (ROS). While excessive levels of ROS can damage cells, they can also modify cellular communication through redox signaling, affecting the structure and function of proteins, which in turn play a part in cancer development. Our lab studies the basic mechanisms of redox biology to decipher the role of ROS in PDA and potentially other KRAS-driven malignancies.

"Do or do not. There is no try." - Master Yoda



Work IN the Chio Lab is generously funded by

  • Pancreatic Cancer Action Network

  • Paul Marks Scholars Program

  • V Foundation

  • National Pancreas Foundation

  • National Cancer Institute

  • Pershing Square Sohn Cancer Research Alliance

  • American Association of Cancer Research

  • Irma T. Hirschl/Monique Weill-Caulier Trust

© Copyright 2018-2024 by Christine Chio Lab. All Rights Reserved.

FOLLOW US on twitter!